DDrare: Database of Drug Development for Rare Diseases

201. アンジェルマン症候群
［臨床試験数：19，薬物数：30（DrugBank：7），標的遺伝子数：22，標的パスウェイ数：20］

Searched query = "Angelman syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Aknemin; Aknemin 50; Betaine; Carbidopa; Creatine; GABOXADOL MONOHYDRATE; GTX-102; Gaboxadol; Gaboxadol monohydrate 0.5 mg; Gaboxadol monohydrate 0.5 mg (intended commercial formulation); Gaboxadol monohydrate 0.5 mg capsule; Gaboxadol monohydrate 2 mg; Gaboxadol monohydrate 2 mg (intended commercial formulation); Gaboxadol monohydrate 2 mg capsule; Gaboxadol monohydrate 5 mg; Gaboxadol monohydrate 5 mg (intended commercial formulation); Levodopa; Levodopa/Carbidopa (4:1); MINOCYCLINE; MINOCYCLINE HYDROCHLORIDE; Metafolin; Minocycline; Nutritional Formulation Containing Exogenous Ketones; OV101; OV101 Regimen 1; OV101 regimen 2; RO7248824; RO7248824/F02-01; RO7248824/F03-01 (Diluent for RO7248824/F02-01; Vitamin B12

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03644693 (ClinicalTrials.gov)	November 1, 2018	13/8/2018	Nutritional Formulation for Angelman Syndrome	Evaluation of the Safety and Tolerability of a Nutritional Formulation in Angelman Syndrome	Angelman Syndrome	Dietary Supplement: Nutritional Formulation Containing Exogenous Ketones;Dietary Supplement: Placebo Formulation	University of Colorado, Denver	NULL	Completed	4 Years	11 Years	All	15	N/A	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03644693
(ClinicalTrials.gov)

November 1, 2018

13/8/2018

Nutritional Formulation for Angelman Syndrome

Evaluation of the Safety and Tolerability of a Nutritional Formulation in Angelman Syndrome

Angelman Syndrome

Dietary Supplement: Nutritional Formulation Containing Exogenous Ketones;Dietary Supplement: Placebo Formulation

University of Colorado, Denver

NULL

Completed

4 Years

11 Years

All

N/A

United States